> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pacira Board Urges Holders To Take Viatris's $36.50 Cash, Up From $31.00 Opening Bid
- URL: https://www.bullished.co/pacira-board-urges-holders-to-take-viatriss-36-50-cash-up-from-31-00-opening-bid-43664943/
- Published: 2026-10-30T12:56:09.000Z
- Updated: 2026-11-05T19:28:34.000Z
- Description: Goldman Sachs called the price fair, and four of five other potential buyers passed, the board says.
- Author: Matteo Parrino
- Tags: Deals, PCRX, Industry: Healthcare

[Pacira BioSciences](https://www.bullished.co/tag/pcrx/), which makes non-opioid pain treatments, unanimously recommended that shareholders tender into Viatris's [$36.50-per-share cash offer](https://www.sec.gov/Archives/edgar/data/0001396814/000114036126041229/ny20084560x1%5Fsc14d9.htm?ref=bullished.co), a premium of approximately 45% to the $25.20 close on October 7, according to a solicitation statement filed Friday. The board says it is the best price reasonably obtainable after a market check of five other potential buyers.

## From $31.00 to $36.50 in cash

Viatris opened with a [$31.00-per-share cash proposal](https://www.sec.gov/Archives/edgar/data/0001396814/000114036126041229/ny20084560x1%5Fsc14d9.htm?ref=bullished.co) dated July 17, then moved to $34.25 on August 17\. On August 26 it offered $35.25 plus a $2.00 contingent value right tied to FDA approval of Pacira's PCRX-201 knee gene therapy.

On October 5 the board told Viatris it would need [$36.50 in cash](https://www.prnewswire.com/news-releases/viatris-announces-commencement-of-tender-offer-to-acquire-pacira-biosciences-inc-302924916.html?ref=bullished.co) to drop the right. Viatris agreed, and the merger agreement was signed October 8\. The final price is $5.50 above the first proposal.

Goldman Sachs, Pacira's financial adviser, opined that [the $36.50 is](https://www.prnewswire.com/news-releases/viatris-announces-commencement-of-tender-offer-to-acquire-pacira-biosciences-inc-302924916.html?ref=bullished.co) "[fair from a financial point of view](https://www.sec.gov/Archives/edgar/data/0001396814/000114036126041229/ny20084560x1%5Fsc14d9.htm?ref=bullished.co)" to holders other than Viatris and its affiliates. The filing puts its estimated fee at about $43 million, all contingent on closing.

## Four buyers passed, one walked

Between August 31 and September 10, Goldman contacted five other potential strategic bidders. Four decided not to proceed, citing lack of strategic fit or focus or insufficient financial capacity.

The fifth, called Party A, a potential buyer in pain management, signed a confidentiality agreement and held a management meeting. On September 24 it told Goldman it would not proceed, citing concerns over Pacira's litigation and patent strategy for EXPAREL, among other things. Only Viatris made a proposal, the board says.

The board also weighed standalone risks: dependence on EXPAREL, patent litigation, manufacturing challenges, and several shareholder activist campaigns that it says diverted management attention.

## Timeline and deal protections

The offer expires one minute after 11:59 p.m. Eastern on November 16, subject to extension. Pacira would owe a $62.0 million termination fee if it ends the deal to accept a superior offer.

The company sold $575.1 million of EXPAREL in 2025, 79% of revenue, according to its annual report. Its other products are ZILRETTA, an injection for osteoarthritis knee pain, and iovera, a cold-based nerve device.

CEO Frank Lee holds 87,775 shares. The filing shows he would also receive about $20.95 million for unvested restricted stock units, plus option, performance-unit and long-term cash payouts.

Holders can tender until the November 16 expiration unless Viatris extends the offer.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SC 14D9 — Pacira BioSciences re: Pacira BioSciences (PCRX)](https://www.sec.gov/Archives/edgar/data/0001396814/000114036126041229/ny20084560x1%5Fsc14d9.htm?ref=bullished.co) — SEC EDGAR
- [Pacira BioSciences (PCRX) Reports Next Week: Wall Street Expects Earnings Growth](https://finance.yahoo.com/markets/stocks/articles/pacira-biosciences-pcrx-reports-next-130031844.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc.](https://www.prnewswire.com/news-releases/viatris-announces-commencement-of-tender-offer-to-acquire-pacira-biosciences-inc-302924916.html?ref=bullished.co) — prnewswire.com

### More on Pacira BioSciences

- [Viatris Starts $36.50-A-Share Cash Tender Offer For Pacira, A Few Cents Above Its Last Close](https://www.bullished.co/viatris-starts-36-50-a-share-cash-tender-offer-for-pacira-a-few-cents-above-its-last-close-68747ece/)
- [Doma Perpetual Sold 2,936,794 Pacira Shares And Now Reports Owning None](https://www.bullished.co/doma-perpetual-sold-2-936-794-pacira-shares-and-now-reports-owning-none-28754ee2/)
- [Viatris Agrees To Buy Pacira For $36.50 A Share In Cash, A $1.65 Billion Deal With A $62.0 Million Break Fee](https://www.bullished.co/viatris-agrees-to-buy-pacira-for-36-50-a-share-in-cash-a-1-65-billion-deal-with-a-62-0-14d71d09/)

[All Pacira BioSciences (PCRX) coverage →](https://www.bullished.co/tag/pcrx/)